14123-79-6

Basic information

• Product Name: Benzeneacetonitrile, a-acetyl-3-chloro-
• CAS NO: 14123-79-6
• Molecular Formula: C10H8ClNO
• Molecular Weight: 193.633
• Mol File: 14123-79-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Benzeneacetonitrile, a-acetyl-3-chloro-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetonitrile, a-acetyl-3-chloro-(14123-79-6)
• EPA Substance Registry System: Benzeneacetonitrile, a-acetyl-3-chloro-(14123-79-6)

Safety Data

• Hazardous Substances Data: 14123-79-6(Hazardous Substances Data)

Upstream product

• 1529-41-5 3-chloro-benzeneacetonitrile 
• 141-78-6 ethyl acetate 
• 75-36-5 acetyl chloride 

Downstream Products

• 62538-18-5 4-(3-chlorophenyl)-5-methyl-1H-pyrazol-3-amine 
• 10557-17-2 1-(3-chlorophenyl)propane-1,2-dione 
• 1346260-42-1 (E)-1-(3-chlorophenyl)-2-(methoxyimino)propan-1-one 
• 66154-45-8 (E)-3-amino-2-(3-chlorophenyl)but-2-enenitrile 
• 921620-90-8 4-bromo-2-(3-chloro-phenyl)-3-oxo-butyronitrile 
• 113494-31-8 2,4-diamino-5-(3-chlorophenyl)-6-methylpyrimidine 
• 14123-60-5 3-chlorophenylacetone 

Relevant articles and documents

N -Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK

NF-κB-inducing kinase (NIK), an oncogenic drug target that is associated with various cancers, is a central signalling component of the non-canonical pathway. A blind screening process, which established that amino pyrazole related scaffolds have an effect on IKKbeta, led to a hit-to-lead optimization process that identified the aminopyrazole 3a as a low μM selective NIK inhibitor. Compound 3a effectively inhibited the NIK-dependent activation of the NF-κB pathway in tumour cells, confirming its selective inhibitory profile.

PYRAZOLO[1.5-A]PYRIMIDIN-7-YL AMINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The invention relates to pyrazolo[1,5a]pyrimidin-7-yl amine derivatives of formula (I) and salts thereof, their use in the treatment of protein kinase dependent diseases.

Organic compounds

The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.